ORAMED PHARMACEUTICALS INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ORAMED PHARMACEUTICALS INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.00M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $1.34M | Mar 27, 2025 |
| FY2022 | Dec 31, 2022 | $904.0K | Mar 6, 2023 |
| FY2022 | Aug 31, 2021 | $2.70M | Mar 6, 2023 |
| FY2021 | Aug 31, 2020 | $2.71M | Nov 24, 2021 |
| FY2020 | Aug 31, 2019 | $2.70M | Nov 24, 2020 |
| FY2019 | Aug 31, 2018 | $2.45M | Nov 27, 2019 |
| FY2019 | Aug 31, 2017 | $2.46M | Nov 27, 2019 |
| FY2018 | Aug 31, 2016 | $641.0K | Nov 28, 2018 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.0K | Mar 26, 2026 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $64.05M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($19.06M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $5.09M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($36.56M) | Mar 6, 2024 |
| FY2021 | Aug 31, 2021 | ($22.99M) | Nov 24, 2021 |
| FY2021 | Aug 31, 2020 | ($11.51M) | Nov 24, 2021 |
| FY2020 | Aug 31, 2019 | ($14.36M) | Nov 24, 2020 |
| FY2019 | Aug 31, 2018 | ($12.73M) | Nov 27, 2019 |
| FY2019 | Aug 31, 2017 | ($10.48M) | Nov 27, 2019 |
| FY2018 | Aug 31, 2016 | ($10.96M) | Nov 28, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($15.09M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($12.78M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($15.77M) | Mar 27, 2025 |
| FY2022 | Dec 31, 2022 | ($12.33M) | Mar 6, 2023 |
| FY2022 | Aug 31, 2021 | ($24.22M) | Mar 6, 2023 |
| FY2021 | Aug 31, 2020 | ($11.76M) | Nov 24, 2021 |
| FY2020 | Aug 31, 2019 | ($14.63M) | Nov 24, 2020 |
| FY2019 | Aug 31, 2018 | ($13.53M) | Nov 27, 2019 |
| FY2019 | Aug 31, 2017 | ($10.77M) | Nov 27, 2019 |
| FY2018 | Aug 31, 2016 | ($10.01M) | Nov 28, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.38M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $6.32M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $8.97M | Mar 27, 2025 |
| FY2022 | Dec 31, 2022 | $9.04M | Mar 6, 2023 |
| FY2022 | Aug 31, 2021 | $20.99M | Mar 6, 2023 |
| FY2021 | Aug 31, 2020 | $10.24M | Nov 24, 2021 |
| FY2020 | Aug 31, 2019 | $13.52M | Nov 24, 2020 |
| FY2019 | Aug 31, 2018 | $11.98M | Nov 27, 2019 |
| FY2019 | Aug 31, 2017 | $10.28M | Nov 27, 2019 |
| FY2018 | Aug 31, 2016 | $7.71M | Nov 28, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.15M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($8.41M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($10.30M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($27.92M) | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | ($11.12M) | Mar 6, 2023 |
| FY2022 | Aug 31, 2021 | ($21.18M) | Mar 6, 2023 |
| FY2021 | Aug 31, 2020 | ($12.44M) | Nov 24, 2021 |
| FY2020 | Aug 31, 2019 | ($12.94M) | Nov 24, 2020 |
| FY2019 | Aug 31, 2018 | ($14.66M) | Nov 27, 2019 |
| FY2019 | Aug 31, 2017 | ($5.83M) | Nov 27, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.0K | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $18.0K | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $254.0K | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $496.0K | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $9.0K | Mar 6, 2023 |
| FY2022 | Aug 31, 2021 | $375.0K | Mar 6, 2023 |
| FY2021 | Aug 31, 2020 | $82.0K | Nov 24, 2021 |
| FY2020 | Aug 31, 2019 | $15.0K | Nov 24, 2020 |
| FY2019 | Aug 31, 2018 | $5.0K | Nov 27, 2019 |
| FY2019 | Aug 31, 2017 | $7.0K | Nov 27, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $230.86M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $155.28M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $220.55M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $161.64M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $177.82M | Mar 6, 2023 |
| FY2021 | Aug 31, 2021 | $128.00M | Nov 24, 2021 |
| FY2021 | Aug 31, 2020 | $44.63M | Nov 24, 2021 |
| FY2020 | Aug 31, 2019 | $34.66M | Nov 24, 2020 |
| FY2019 | Aug 31, 2018 | $47.40M | Nov 27, 2019 |
| FY2018 | Aug 31, 2017 | $38.71M | Nov 28, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $199.74M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $146.27M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $163.82M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $151.81M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $166.45M | Mar 6, 2023 |
| FY2021 | Aug 31, 2021 | $115.77M | Nov 24, 2021 |
| FY2021 | Aug 31, 2020 | $32.88M | Nov 24, 2021 |
| FY2020 | Aug 31, 2019 | $19.39M | Nov 24, 2020 |
| FY2020 | Aug 31, 2018 | $31.11M | Nov 24, 2020 |
| FY2019 | Aug 31, 2017 | $19.24M | Nov 27, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($123.44M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($176.62M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($157.56M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($163.08M) | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | ($126.52M) | Mar 6, 2023 |
| FY2021 | Aug 31, 2021 | ($114.85M) | Nov 24, 2021 |
| FY2021 | Aug 31, 2020 | ($92.61M) | Nov 24, 2021 |
| FY2020 | Aug 31, 2019 | ($81.10M) | Nov 24, 2020 |
| FY2019 | Aug 31, 2018 | ($69.22M) | Nov 27, 2019 |
| FY2018 | May 31, 2018 | $700.0K | Nov 28, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $45.95M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $54.42M | Mar 26, 2026 |
| FY2023 | Dec 31, 2023 | $9.06M | Mar 6, 2024 |
| FY2023 | Dec 31, 2022 | $40.46M | Mar 6, 2024 |
| FY2021 | Aug 31, 2021 | $77.25M | Nov 24, 2021 |
| FY2021 | Aug 31, 2020 | $19.30M | Nov 24, 2021 |
| FY2021 | Aug 31, 2019 | $3.33M | Nov 24, 2021 |
| FY2020 | Aug 31, 2018 | $5.00M | Nov 24, 2020 |
| FY2019 | Aug 31, 2017 | $3.97M | Nov 27, 2019 |
| FY2019 | Aug 31, 2016 | $3.91M | Nov 27, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $25.0K | Mar 6, 2023 |
| FY2019 | Aug 31, 2019 | $9.66M | Nov 27, 2019 |
| FY2019 | Aug 31, 2018 | $11.39M | Nov 27, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 27, 2025 |
| FY2022 | Dec 31, 2022 | 0 | Mar 6, 2023 |
| FY2022 | Aug 31, 2021 | 0 | Mar 6, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 27, 2025 |
| FY2022 | Dec 31, 2022 | 0 | Mar 6, 2023 |
| FY2022 | Aug 31, 2021 | 0 | Mar 6, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 39.28M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 39.92M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | 40.34M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 39.56M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | 38.16M | Mar 6, 2023 |
| FY2021 | Aug 31, 2021 | 35.29M | Nov 24, 2021 |
| FY2021 | Aug 31, 2020 | 23.68M | Nov 24, 2021 |
| FY2020 | Aug 31, 2019 | 17.38M | Nov 24, 2020 |
| FY2019 | Aug 31, 2018 | 17.37M | Nov 27, 2019 |
| FY2018 | Aug 31, 2017 | 13.67M | Nov 28, 2018 |